Recent Company News

• 09:41 PM ET Apr 23, 2025
  

  StreetAccount Summary - Trading higher/lower: Australia & New Zealand midday

• 09:17 AM ET May 15, 2025
  

  StreetAccount Summary - US Pre-market trading update

• 08:03 PM ET May 14, 2025
  

  Mesoblast receives seven years of orphan-drug exclusive approval from FDA for Ryoncil (A$1.78, 0.00)

• 08:14 PM ET Apr 29, 2025
  

  Mesoblast reports Q3 net cash from / (used in) operating activities ($12.7M) - Appendix 4C (A$1.85, +0.01)